Starting now, the spectrophotometers of Analytik Jena's SPECORD® PLUS series will be complementing the product range of the Swiss company SOTAX, a leading solutions provider in the pharmaceutical industry.
With this mutually beneficial cooperation, Analytik Jena AG is taking the chance to embrace new opportunities and new market potential in the pharmaceutical industry worldwide. For SOTAX AG, the partnership with the Jena-based high tech company is an opportunity to strengthen its position as a leading dissolution systems provider.
The UV/Vis spectrophotometers of the SPECORD® PLUS series can easily be coupled with the SOTAX online dissolution systems. The photometers are completely integrated into the system software. This combination offers a sophisticated automatic dissolution test system for online UV/Vis measurements. In the pharmaceutical industry, dissolution devices are used for testing drugs. The devices simulate the dissolution of agents to be tested in the body and provide both qualitative and quantitative information.
In the pharmaceutical industry, SPECORD® PLUS can also be used as a stand-alone solution for photometric analysis. The control and analysis software WinASpect® PLUS quickly provides valid results. Thanks to the 8-cell and 2x 8-cell changers, the degree of automation is very high.
The SPECORD® PLUS instruments conform to all international pharmacopoeia and are certified for installation qualification and operational qualification. They thus fulfill the strict requirements for equipment qualification in the pharmaceutical industry.
Thomas Pfammatter, SOTAX CEO: "Since we've installed Analytik Jena's SPECORD® PLUS photometer with our SOTAX instruments, it has already proven extremely precise, robust and reliable. Equipped with an 2x 8-cell changer it is the ideal photometer for a double UV online dissolution system. Our customers can now benefit from the complete package: SOTAX offers and supports the integrated configuration with a SPECORD® PLUS photometer (qualification, repair, maintenance).”